HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China
By Dr. Matthew Watson
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first patient received their first dose on October 27, 2021.
Here is the original post:
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China
- 001 Eton Pharmaceuticals Announces Closing of Public Offering [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 002 Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute... [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 003 Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 004 Stabilization measures taken [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 005 Coherus BioSciences Announces New Employment Inducement Grants [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 006 Biomerica Reports Fiscal 2021 1st Quarter Financial Results [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 007 German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 008 Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 009 SPACs Show Investors Faster, Simpler Way to Go Public [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 010 Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 011 Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 012 Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 013 Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 014 CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 015 Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 016 Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 017 Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 018 Theratechnologies Appoints Two New Board Members [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 019 Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 020 First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- 021 Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 022 Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 023 UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 024 Replimune Appoints Tanya Lewis to the Board of Directors [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 025 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 026 Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 027 Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 028 Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 029 Orion upgrades full-year outlook for 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 030 Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 031 Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR... [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 032 Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 033 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and... [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 034 Rafarma Closes Biocogency Merger [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 035 Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 036 Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 037 Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 038 Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 039 Cocrystal Pharma Provides Update on Influenza A Program [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 040 Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System [Last Updated On: October 19th, 2020] [Originally Added On: October 19th, 2020]
- 041 Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 042 Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 043 TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 044 BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 045 AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 046 Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 047 Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 048 CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 049 Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 050 ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 051 ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 052 SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 053 MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 054 Syneos Health® Launches Kinetic™ Omnichannel Capability to Accelerate Modern Customer Engagement [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 055 Interim report for the first nine months of 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 056 PCI Biotech: Preclinical research collaboration with big pharma ended [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 057 Orion Group Interim Report 1-9/2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 058 Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 059 MDxHealth Provides Q3-2020 Business Update [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 060 Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020 [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- 061 Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 062 Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 063 Bone Therapeutics SA: Information on the total number of voting rights and shares [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 064 Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 065 First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 066 KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 067 Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 068 Coherus BioSciences to Report Third Quarter Financial Results on November 5th [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 069 BioCryst to Report Third Quarter 2020 Financial Results on November 5 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 070 Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 071 Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 072 Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 073 Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 074 Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 075 X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 076 Retrophin Announces Agreement to Acquire Orphan Technologies [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 077 Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 078 ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary... [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 079 Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
- 080 Update on current trading for Q3 2020 and updated full-year outlook for 2020 [Last Updated On: October 23rd, 2020] [Originally Added On: October 23rd, 2020]
Global News Feed
Comments Off on HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China |
October 28th, 2021
This author published 6272 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research